Prenatal Antiseizure Medication Exposure Linked to Impaired Fetal Growth
Personalized briefing
Discovery of the day · Neurology
Antiseizure medication use in pregnancy and the risk of poor fetal growth in the EURAP international registry: a prospective cohort study
Dear Damien Boorman, this is your personalized scientific intelligence briefing — curated for your work in Neurology.
Key finding
Medicine · Neurology
Discovery of the day
Analysis of the EURAP international registry reveals that poor fetal growth is a clinically important adverse outcome of prenatal antiseizure medication exposure, independent of congenital malformations and neurodevelopmental effects. The risk of impaired fetal growth varies across individual antiseizure monotherapies and specific drug combinations, and increases with the number of concomitant medications prescribed during pregnancy. These findings directly inform risk stratification and individualized treatment selection during preconception counseling, aligning with your translational research expertise in improving patient well-being through clinically meaningful neuroscience.
Novelty
88%
Rigor
93%
Significance
91%
Validity
89%
Clarity
94%
Advertisement
GroupRFQ — join group deals on lab & medical equipment. Pool orders, unlock volume pricing. See open deals →
Your briefing is personalized based on your selected fields, keywords, and research interests.
